Jeong Y, Jusko W
AAPS J. 2022; 24(5):96.
PMID: 36042121
PMC: 9589903.
DOI: 10.1208/s12248-022-00739-5.
Alpert N, Pelletier-Galarneau M, Kim S, Petibon Y, Sun T, Ramos-Torres K
Front Physiol. 2020; 11:491.
PMID: 32499721
PMC: 7243673.
DOI: 10.3389/fphys.2020.00491.
Melendez D, Marti S, Pajor E, Sidhu P, Gellatly D, Janzen E
PLoS One. 2019; 14(5):e0217518.
PMID: 31125384
PMC: 6534336.
DOI: 10.1371/journal.pone.0217518.
Melendez D, Marti S, Pajor E, Sidhu P, Gellatly D, Moya D
PLoS One. 2018; 13(11):e0207289.
PMID: 30500846
PMC: 6269141.
DOI: 10.1371/journal.pone.0207289.
Ceballos L, Krolewiecki A, Juarez M, Moreno L, Schaer F, Alvarez L
PLoS Negl Trop Dis. 2018; 12(1):e0005945.
PMID: 29346367
PMC: 5773000.
DOI: 10.1371/journal.pntd.0005945.
The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium.
Li J, Hao H, Cheng G, Wang X, Ahmed S, Shabbir M
Sci Rep. 2017; 7(1):11676.
PMID: 28916830
PMC: 5601478.
DOI: 10.1038/s41598-017-12294-7.
Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac.
Elzayat E, Abdel-Rahman A, Ahmed S, Alanazi F, Habib W, Abou-Auda H
Saudi Pharm J. 2017; 25(5):688-695.
PMID: 28725140
PMC: 5506666.
DOI: 10.1016/j.jsps.2016.10.004.
Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration.
Sattar A, Xie S, Huang L, Iqbal Z, Qu W, Shabbir M
Front Pharmacol. 2016; 7:236.
PMID: 27536243
PMC: 4971586.
DOI: 10.3389/fphar.2016.00236.
Letter to the editor.
Mayersohn M
Curr Ther Res Clin Exp. 2014; 72(3):138-9.
PMID: 24648583
PMC: 3957163.
DOI: 10.1016/j.curtheres.2011.05.001.
Plasma and ocular prednisolone disposition after oral treatment in cats.
Del Sole M, Schaiquevich P, Aba M, Lanusse C, Moreno L
Biomed Res Int. 2013; 2013:209439.
PMID: 24069591
PMC: 3773412.
DOI: 10.1155/2013/209439.
Relative bioavailability and comparative clinical efficacy of different ivermectin oral formulations in lambs.
Suarez G, Alvarez L, Castells D, Correa O, Fagiolino P, Lanusse C
BMC Vet Res. 2013; 9:27.
PMID: 23398629
PMC: 3599275.
DOI: 10.1186/1746-6148-9-27.
Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics.
Wu Y, Bauer L, Ballard R, Ferriero D, Glidden D, Mayock D
Pediatrics. 2012; 130(4):683-91.
PMID: 23008465
PMC: 3457622.
DOI: 10.1542/peds.2012-0498.
Pharmacokinetics of recombinant bifunctional fusion proteins.
Chen X, Zaro J, Shen W
Expert Opin Drug Metab Toxicol. 2012; 8(5):581-95.
PMID: 22428984
PMC: 3718553.
DOI: 10.1517/17425255.2012.673585.
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
Flygare J, Beresini M, Budha N, Chan H, Chan I, Cheeti S
J Med Chem. 2012; 55(9):4101-13.
PMID: 22413863
PMC: 3366583.
DOI: 10.1021/jm300060k.
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.
Muscal J, Thompson P, Giranda V, Dayton B, Bauch J, Horton T
Cancer Chemother Pharmacol. 2009; 65(3):419-25.
PMID: 19526240
PMC: 2953793.
DOI: 10.1007/s00280-009-1044-3.
Eprinomectin in dairy zebu Gobra cattle (Bos indicus): plasma kinetics and excretion in milk.
Bengone-Ndong T, Ba M, Kane Y, Sane I, Sutra J, Alvinerie M
Parasitol Res. 2006; 98(6):501-6.
PMID: 16416124
DOI: 10.1007/s00436-005-0103-x.
Absolute bioavailability and absorption profile of cyanamide in man.
Colom H, Prunonosa J, Peraire C, Domenech J, Azcona O, Torrent J
J Pharmacokinet Biopharm. 2000; 27(4):421-36.
PMID: 10826131
DOI: 10.1023/a:1020969106163.
Some pharmacokinetic parameters of eprinomectin in goats following pour-on administration.
Alvinerie M, Lacoste E, Sutra J, Chartier C
Vet Res Commun. 1999; 23(7):449-55.
PMID: 10598075
DOI: 10.1023/a:1006373609314.
Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits.
Callender D, Jayaprakash N, Bell A, Petraitis V, Petraitiene R, Candelario M
Antimicrob Agents Chemother. 1999; 43(4):972-4.
PMID: 10103214
PMC: 89240.
DOI: 10.1128/AAC.43.4.972.
Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.
Ghetie M, Podar E, Ilgen A, Gordon B, UHR J, Vitetta E
Proc Natl Acad Sci U S A. 1997; 94(14):7509-14.
PMID: 9207122
PMC: 23852.
DOI: 10.1073/pnas.94.14.7509.
